Pfizer expects 2021, 2022 COVID-19 vaccine sales to total at least $65 billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pfizer (PFE) Stock Rallies on Beat-and-Raise, Analysts Divided on How Shares Will React
November 2, 2021 8:44 AM EDTShares of Pfizer (NYSE: PFE) are trading over 3% higher in pre-open Tuesday after the company reported better-than-expected Q3 results and raised its FY guidance.
Pfizer reported EPS of $1.37 to easily beat the analyst estimate of $1.08. Revenue for the quarter came in at $24.1 billion versus the consensus estimate of $22.68 billion.
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: More than 75% of the revenues we have recorded up through third-quarter 2021 for Comirnaty(1) have come from... More
